<DOC>
	<DOCNO>NCT01278069</DOCNO>
	<brief_summary>Myeloid Sarcoma ( granulocytic Sarcoma Chloroma ) well define WHO . However , currently data prevalence , sit occurence thr prognostic value patient AML find . Information condition base retrospective analysis since study try define role myeloid sarcoma AML far . This observational trial include adult patient newly diagnose relapse AML order perform 18FDG-PET-CT image prior induction chemotherapy . Furthermore , second 18FDG-PET-CT perform induction chemotherapy define responsiveness tumor chemotherapy . The primary endpoint study prevalence 18FDG-PET-CT positive extramedullary AML manifestation ( myeloid sarcoma ) patient newly diagnose relapse AML .</brief_summary>
	<brief_title>PET-CT AML Detection Extramedullary AML Manifestations</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients newly diagnose relapse AML AML FAB M02 , M47 Signed informed consent patient information Male female patient AML age 1880 18FDGPETCT available within period 5 day diagnosis AML AML FAB M3 ( Promyelocytic Leukemia ) lack willingness cooperate pregnancy insufficient contraception 18FDGPETCT available within period 5 day diagnosis AML Medical condition patient require immediated start chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Acute myeloid Leukemia</keyword>
	<keyword>Myeloid Sarcoma</keyword>
	<keyword>Extramedullary Acute myeloid Leukemia</keyword>
	<keyword>18FDG-PET-CT</keyword>
</DOC>